Adela
Adela's mission is to develop innovative and accessible technologies that harness biology and change the way we diagnose and treat disease. Adela's genome-wide methylation enrichment technology was originally developed by Chief Scientific Officer Dr. Daniel De Carvalho, PhD, at University Health Network's Princess Margaret Cancer Centre. Adela is initially planning to develop the technology for use across the entire cancer continuum—for detection, diagnosis, and management of disease. The company values clarity, empathy, and iterative collaboration, and is committed to building psychologically safe environments that support learning and growth. Adela fosters diversity and inclusion, embracing the unique qualities and perspectives of all individuals and providing equal employment opportunities.
Adela values clarity, empathy, and iterative collaboration, and is committed to building psychologically safe environments that support learning and growth. The company embraces diversity and inclusion, celebrating the unique qualities and perspectives of all individuals, and fosters a workplace where everyone belongs.
Website
adelabio.com
Company Size
11-50 employees
Industry
Other Nondepository Credit Intermediation
Other opportunities you might be interested in
Taiwan Semiconductor Manufacturing Company
Netspeed
Anywhere
Palo Alto Networks
Cisco
Cisco